Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 3, 2021

View Archived Issues

JDQ-443: a mutant-selective, irreversible inhibitor of KRAS G12C with an unprecedented binding mode

miR-7-5p and miR-375-3p: new circulating markers of pituitary NETs

2,3-Disubstituted pyridine IDO1 inhibitors with improved drug-like properties

Thymic stromal lymphopoietin and T cells shown to homeostatically regulate sebum production

Study identifies cell state as oncogene enabler

AMMS patents carbonic anhydrase inhibitors

Bristol Myers Squibb presents PADI4 inhibitors

Haim Bio synthesizes new antiepileptics

Stingray Therapeutics presents new ENPP1 inhibitors

AstraZeneca discloses adenosine receptor antagonists

Variants in PI4KA linked to severe neurometabolic disorder

New kratom derivatives identified with mu-opioid receptor modulatory activity

Deficient H2A.Z deposition tied to uterine leiomyoma

Celsion reports in vivo data on PLACCINE DNA vaccine platform against SARS-CoV-2

QGC-606 prevents LV dysfunction in mice post-MI

LEO Pharma's novel IL-17A/IL-17AR interaction modulator for the oral treatment of psoriasis

New FPR2 agonists target inflammation in Alzheimer's disease

Discovery and preclinical characterization of novel cyclic dinucleotide STING agonists

SymBio collaborates with NCCS to explore use of brincidofovir in EBV-positive lymphoma

SBIR grant supports Felix Biotechnology's work on engineering bacteriophage

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026